ESHRE PGT Consortium data collection XXII-XXIV: PGT analyses from 2019 to 2021†

Area of Science:

• Reproductive Medicine
• Genetics
• Embryology

Background:

• The European Society of Human Reproduction (ESHRE) Preimplantation Genetic Testing (PGT) Consortium has collected data since 1997.
• Previous analyses covered 21 datasets, with an overview of the first decade of PGT data.

Purpose of the Study:

• To analyze trends and developments in preimplantation genetic testing (PGT) practices between 2019 and 2021.
• To compare recent PGT trends with data from previous years.

Main Methods:

• Data were voluntarily submitted by 45 European PGT centers for analyses conducted between January 1, 2019, and December 31, 2021.
• The data collection platform shifted to a per-analysis basis, including biopsy methods, diagnostic technologies, and clinical outcomes.
• Clinical outcomes were calculated based on embryo transfers within two years of analysis, stratified by biopsy day.

Main Results:

• A total of 14,731 PGT analyses were reported: 3782 for PGT-M, 874 for PGT-SR, 8492 for PGT-A, and 1583 for combined testing.
• Trophectoderm biopsy use increased for PGT-M (49%) and remained high for PGT-A (98%) and combined cases (96%).
• Genome-wide analysis became standard for PGT-A (99%), while targeted methods (PCR/FISH) prevailed for PGT-M (86-88%) and PGT-SR (55-56%). Day 5 biopsies showed better outcomes than Day 3 or Day 6.

Conclusions:

• Trophectoderm biopsy with comprehensive whole-genome testing is prevalent in PGT-A and combined testing.
• Single-cell targeted testing remains the primary method for PGT-M and PGT-SR.
• The ESHRE Consortium datasets are crucial for monitoring technological and clinical outcome trends in PGT.